welcome
About us
Newsletter
News Widget
Media Inquiries

Summary

Ozempic Linked to Health Risks

This is a Glucagon news story, published by Live Science, that relates primarily to GLP-RAs news.

Glucagon news

For more Glucagon news, you can click here:

more Glucagon news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Live Science news

For more news from Live Science, you can click here:

more news from Live Science

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

insulin

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest receptor agonists news, diabetes news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

loss drugs
Live Science

Live Science

•

Health

Health

Ozempic-style drugs tied to more than 60 health benefits and risks in biggest study-of-its-kind

Live Science
Summary
Nutrition label

81% Informative

Glucagon -like peptide peptide 1 receptor agonists ( GLP-1RAs ) have become increasingly popular over the past decade for the treatment of type 2 diabetes and obesity.

In a new study, scientists compiled what they say is the clearest ever picture of the effectiveness and risks associated with taking GLP-RAs .

The study assessed the health of 215,000 people with diabetes over four years .

VR Score

90

Informative language

93

Neutral language

82

Article tone

semi-formal

Language

English

Language complexity

60

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

11

https://pubmed.ncbi.nlm.nih.gov/37821008/https://generalmedicinegeriatrics.wustl.edu/people/ziyad-al-aly-md-fasn/https://www.ncbi.nlm.nih.gov/books/NBK551568/https://www.guysandstthomas.nhs.uk/health-information/diabetes-medicines-glp-1-agonistshttps://www.gla.ac.uk/schools/cardiovascularmetabolic/staff/naveedsattar/https://www.sciencemediacentre.org/expert-reaction-to-a-study-investigating-the-health-benefits-and-risks-associated-with-glp-1-receptor-agonists/https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313https://www.ozempic.com/https://www.kcl.ac.uk/people/penelope-wardhttps://www.va.gov/https://www.wegovy.com/

Source diversity

11

pubmed.ncbi.nlm.nih.govgeneralmedicinegeriatrics.wustl.eduwww.ncbi.nlm.nih.govwww.guysandstthomas.nhs.ukwww.gla.ac.ukwww.sciencemediacentre.orgalz-journals.onlinelibrary.wiley.comwww.ozempic.comwww.kcl.ac.ukwww.va.govwww.wegovy.com

Affiliate links

2

https://go.redirectingat.com/?id=92X1590019&xcust=livescience_us_8897327049150410072&xs=1&url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-024-03412-w&sref=https%3A%2F%2Fwww.livescience.com%2Fhealth%2Fmedicine-drugs%2Fozempic-style-drugs-tied-to-more-than-60-health-benefits-and-risks-in-biggest-study-of-its-kindhttps://www.awin1.com/awclick.php?awinmid=2961&awinaffid=103504&clickref=livescience-us-5175322149437919698&p=https%3A%2F%2Fwww.magazinesdirect.com%2Faz-magazines%2F6936539%2Fhow-it-works-magazine-subscription.thtml
Read full article